We estimate a dynamic multi-stage duration model to investigate how early detection of diabetes can delay the onset of lower extremity complications and death. We allow for partial observability of the disease stage, unmeasured heterogeneity, and endogenous timing of diabetes screening.
Introduction
According to the U.S. Center for Disease Control (CDC) 75% of health care expenditures and 70% of all deaths in the U.S. are attributable to chronic diseases, including heart conditions, cancer, stroke, and diabetes (CDC 2009).
Earlier detection of these chronic diseases can yield substantial savings and better health outcomes. To achieve these goals, the A¤ordable Care Act (ACA) of 2010 subsidizes not only primary preventive measures, such as improvements in diet, but also secondary preventive measures. For example, beginning in 2014 all insurance plans will be required to cover many screening tests without any co-payment. However, the empirical evidence that increased screening will save resources or even improve health outcomes is mixed (Cutler 2008) . Knowing earlier that an individual has a chronic disease does not imply that screening can delay disease progression or increase longevity.
The "gold standard" for evaluating the bene…ts versus costs of alternative screening policies is the randomized controlled trial (RCT). RCTs provide a simple approach to solve the problem of unobserved heterogeneity, but their usefulness for policy evaluations can be limited in many important situations.
When the outcomes monitored are relatively rare, they can be quite expensive.
They are di¢ cult to conduct for long follow-up periods. In the context of dynamic decision-making, the treatment protocols speci…ed in RCTs may not yield results generalizable to community settings. This is especially the case when there are many di¤erent outcomes occurring over long time horizons and numerous intermediate outcomes that might require additional interventions.
These are all key issues when one studies diabetes, and the sample size of an RCT would have to be very large and the follow-up period very lengthy for it to have su¢ cient statistical power and time to measure many relevant relationships.
A potentially important alternative is to use observational data like we do in this study. Large, longitudinal, administrative data sets are becoming increasingly available to researchers, but their e¤ective use requires one to address directly how unobserved heterogeneity impacts both observed treatment choices and outcomes over time. Econometric solutions for dealing with such issues in analyzing observational data have been developed, including for dynamic problems like those examined here, but there is still much progress to be made. In this study we incorporate many of these advances and add in a key component that it relevant for studying diabetes and many other diseases.
Diabetes mellitus is a complex chronic disease. It can a¤ect eyesight, kidneys, cardiovascular systems, and nervous systems a¤ecting the lower extremities. The incidence of diabetes is increasing in the U.S. and elsewhere, re ‡ecting increased obesity of the population in part. The disease progresses through several stages, each with increasingly debilitating consequences. Once an individual reaches a more advanced diabetes stage it is impossible to undo the physiological damage; it can eventually lead to death. Prevalence is high among the elderly (Sloan et al. 2008 ). The early stages of the disease are typically non-symptomatic, but without interventions, irreversible physiological damage will continue to accrue. Like many other chronic illnesses, diabetes can be much more costly to treat if detected later. Regular screening for diabetes potentially can help the patient and her physician recognize when it is appropriate to undertake behavioral modi…cations and start medications and other therapies to slow the disease's progression.
Screening is costly, and the optimal screening regimen depends on a comparison of the marginal bene…t and the marginal cost of screening. The marginal bene…t from more frequent screening depends on the probability that screening will reveal useful information and the value of this information in slowing the disease's progression. This is the primary focus of this paper. This study uses a dynamic multi-stage discrete duration model to investigate the e¤ective-ness of early detection of diabetes mellitus through screening in delaying the progression of complications and death.
An evaluation of screening for diabetes encounters at least four econometric issues. First, ascertainment of diagnosis in particular and care more generally is endogenous. Second is the importance of partial observability of the disease state; the person could have the disease for a long time without being diagnosed.
Third, since people and diseases di¤er in aspects unobservable to the researcher, there is likely unobserved heterogeneity. Fourth, the probability of adverse outcomes increases with duration and progression of the disease.
Our estimation strategy deals with each of these four econometric problems. We address endogeneity and unmeasured heterogeneity issues by using discrete factor models (Heckman and Singer, 1984; Mroz 1999 ). This approach ers. We simultaneously account for multiple disease stages, partial observability of disease progression, endogeneity of the timing of diagnoses, and health outcomes. We control for partial observability by modeling empirically all potential exact times of disease (or stage) onset and integrating over all these potential onset times. The bounds for these integrations come from the last time period a person was known to not have the disease and the …rst time the individual was known to have the disease.
These time periods during which we are uncertain about precisely when the individual progressed to the next disease stage constitute a key feature of this analysis. Not only is this an econometric issue to be addressed; it is a real, substantive issue for analyzing disease progression and treatments. Many individuals will not recognize that they have progressed to diabetes or to more advanced stages if they do not see a health care professional who can diagnose their condition. If the period of time during which the disease is present but unobserved and untreated is long, then the individual may progress much more rapidly to more severe disease stages, possibly resulting in amputation or death.
We …nd that earlier diagnosis of diabetes, and presumably the treatments that follow diagnosis, delays the onset of lower extremity complications including amputation. For example, a one year delay in the diagnosis of diabetes increases the probability that …ve years later she will have a lower extremity complication (or worse) by 11% (6.6% points out of a baseline of 59%). Transitions to high severity lower extremity complications, or worse, within …ve years would increase by 27%. However, because the number of individuals who transition to severe stages is relatively low, the total number of additional high severity LEC cases is correspondingly low. Our parameter estimates also allow us to conduct counterfactual analysis and policy simulations. For example a policy that restricts the number of visits that Medicare covers to two per year at most for healthy individuals will save $476 per bene…ciary, but it would cost about 0.004 per person in years of life during a 15-year span. These would imply an implicit value of a year of life of about $119,000.
The rest of the paper is organized as follows: Section 2 provides a background on diabetes and the decision process to screen. Section 3 describes the econometric strategy and Section 4 the data. Section 5 presents our empirical speci…cation, including the method for accounting for endogeneity of treatments, which is followed by results in Section 6. Section 7 discusses the marginal e¤ects and policy simulations. Finally, Section 8 presents conclusions and implications.
Background
Diabetes mellitus is a complex disease, potentially adversely a¤ecting several organ systems, including the eyes, the cardiovascular system, the kidneys, and legs and feet. It reduces life expectancy. Complications of the legs and feet, lower extremity complications (LECs), are common. They may be classi…ed into stages, with each successive stage being increasingly more severe. In this study, we de…ned …ve mutually exclusive stages (Table 1) Each period the individual has the option of visiting a physician who diagnoses whether or not she has diabetes and the stage of the disease from D 1 to D 4 . Early diagnosis of D 1 as well as later stages leads to earlier treatment. This potentially can slow down the disease progression and adverse health shocks. If these screening visits were costless, the individual would visit a physician every period and the disease would be perfectly monitored. In practice very few individuals visit a physician each period for screening, since it is costly in terms of time and out-of-pocket medical or other expenditures (e.g., for transportation).
Several factors a¤ect the individual's decision to have a screening visit including time since last visit and whether she has some disease symptoms. Writing, solving, and estimating a complete dynamic optimization model is outside the scope of our study. Instead we model the individual's decision to have a screening visit at each point in time and examine how this interacts with disease progression. This is a function of observed and unobserved disease characteristics, and observed individual and location speci…c characteristics as well as unobserved heterogeneity.
Screening visits serve two purposes. First, they assess whether or not the individual's diabetes' status has progressed since the previous screening visit.
Second, if the disease has progressed, the patient and her physician use this information to adjust the sequence of treatments. These sequences of treatment choices a¤ect the patient's probabilities of progressing to more advanced disease stages. The actual set of treatments chosen by the patient, however, is not observed in our data set. As a consequence, we assume that the impacts of these treatment decisions can be captured by the measures of each disease stage's durations in the hazard functions of moving to more severe, higher disease stages. Provided that the distributions of the future disease stages and exogenous variables are captured by the current period's variables (a …rst order Markov assumption), 1 our formulations approximate the optimal sequence of screening visits and treatment decision rules chosen by the patient and her health care provider. 1 That is, in a stochastic dynamic optimization model the expected value of the future value function conditional on any set of choices made today can be perfectly forecast by current period variables. See, for example, Blundell, Magnac, and Meghir(1997) We break time into discrete time intervals. We allow for three arbitrary time we model potential disease progression through its initial two stages. After the …rst screening visit (t > t F V ), we model the quarterly progression of diabetes 2 We exclude from the analysis any individual who had already advanced to disease stage 3 (D 3 ) by the time of the …rst observed screening visit after becoming 65. In preliminary analyses, we used having reached stage 3 diabetes or worse by the time of the …rst post-age 65 visit as an endogenous selection mechanism. This had little e¤ect on the parameter estimates for visits and disease progression after age 65, but it greatly increased the computational burden. Thus, we simpli…ed the model by eliminating these severely ill individuals and focusing on individuals whose length of time in the various diabetes stages are more precisely measured. 
where (z) is the logit function
is a vector of time invariant and time varying explanatory variables, e k is the unmeasured heterogeneity assumed to be discrete with K heterogeneity points and D1 (:) is a polynomial of degree J K 1.
Let t Dj be the time at which the individual progresses to D j (j = 1; :::; 4). 
where 
Visits and Health Shocks
The probability of a screening visit in period t (t = t F V + 1; :::; T ) depends on the current stage D j (j = 1; :::; 4) as follows:
where 0l t D l is a quadratic function with an intercept. We restrict V and V (e k ) to be the same irrespective of disease stage, but allow for di¤erent intercepts and di¤erent duration coe¢ cients for each stage. For a healthy individual, this probability is (Z t V + V (e k )) and for an individual that only progressed to D 1 , this probability is given by
. Among the regressors are variables a¤ecting the probability of a visit but otherwise not af-fecting health or diabetes progression (exclusion restrictions). We use distances to the nearest health providers as our exclusion restriction. The speci…cation of the probability of the …rst visit is identical to eq. (3), but we do not restrict V and V (e k ) to be the same as in eq. (3).
Finally, let d 1 and d 2 be two observable health outcome shocks, amputation and death. As the disease progresses, the hazard of such an outcome occurring is likely to increase. For an individual at stage D j , the hazard of d ct during each time period is
for c = 1; 2. As with visits we restrict the coe¢ cients ( cd ) to be the same irrespective of the disease stage, but allow for di¤erent intercepts and di¤erent duration coe¢ cients for each disease stage the person entered by date t.
Unmeasured Heterogeneity
Unmeasured heterogeneity, e.g., overall unmeasured health, a¤ects the hazard of progression to a higher disease stage, probabilities of a screening visit, amputation and death. For each of the events we assume a discrete heterogeneity distribution which we model as a polynomial
where k = 1; :::; K, K is the number of heterogeneity points, J K 1 is the degree of the polynomial, and q = 1; :::; Q where Q = 12 is the number of equations in the model. We estimate Pr (e k ) subject to the restrictions that each probability is non-negative and
Pr (e k ) = 1. Note that the underlying heterogeneity terms e k = (k 1) = (K 1) for k = 1; : : : ; K form a set of equally spaced points on the unit interval. If we were to allow the heterogeneity terms in each of the 12 equations to be a K 1 order polynomial, then in each equation it would be possible to map from this set of equally spaced K points on the unit interval to any arbitrary set of K or fewer points on the real line. With a large enough value of K, the resulting multivariate distribution then could represent any arbitrary 12-dimensional discrete distribution function with a …nite number of support points. 3 
The Likelihood Function
Based on the hazards and probabilities (eqs. 1-4), the likelihood function for an individual with any possible transition combination conditional on unmeasured heterogeneity e k and the matrix of all possible explanatory variables
L t D1 ; :::; t D4 ; T;
3 The formulation used by Mroz (1999) is a special case of this. To obtain his linear discrete factor distribution, one would use K 1 degree polynomials restricted to be proportional to each other across all pairs of the 12 components. is given by L D4 t D1 ; :::; t D4 ; T;
where Pr (D 1 = t D1 ) is the probability of an individual contracting D 1 at period t D1 and Pr D j = t Dj for j = 2; :::; 4 is the probability of an individual
is the probability of having the …rst
is the probability of the sequence of visits from
2 is the probability of the sequence of outcomes d ct from t = t F V to t = T . Appendix A contains the details on the
, and L D4 (:).
Partial Observability and Early Detection of a Disease
To avoid the unrealistic assumption that the individual's stage is continuously monitored at each t (i.e., the individual visits a physician every period), we incorporate partial observability by the individual and her physician of the disease stage into the likelihood function. We do this by integrating over the possible time spans during which an individual is known from our data to have progressed to a higher disease stage. 5 In particular, we assume that the …rst date at which a claim reports a diabetes stage is the latest period (t max j ) a person could enter that stage. L t min;D1 ; :::; t max;D4 ; T;
Uncertainty about precisely when the individual progressed to the next stage is a key feature of this analysis, not just an econometric issue to be addressed.
If the time during which the disease is present but unobserved and untreated is long, then the individual may progress to more severe disease stages much more
rapidly. in eq (7).
Estimation
Finally, the unconditional log-likelihood function is:
Pr (e k ) L t min D1i ; :::; t max D4i ; T i ;
where is the vector of parameters and Pr (e k ) is the probability of the discrete heterogeneity point e k . 6 We maximize this likelihood function using GQOPT with respect to all of the parameters in in the twelve outcome equations.
We estimate the likelihood with di¤erent number of heterogeneity points (K), including K = 1 (no heterogeneity and no correlation among the equations).
We report the results for eight points of support (K = 8) and third degree polynomials in the underlying heterogeneity factor (J = 3). Adding the eighth point of support barely improved the likelihood function value over using seven points of support.
Data
We use data from interviews conducted for the National Long-Term Care Survey Table   2 ), the time periods used in this study. A quarter may be su¢ cient for some individuals to notice disease symptoms and visit a doctor. Moreover, visits more frequent than once in a quarter are likely to be predominantly follow up visits.
Empirical Speci…cation
There are 
Dependent Variables
Stages: A person is in one or more of …ve mutually exclusive stages during a quarter. When a person transitions to a higher stage in a quarter, the person is assumed to have been in the higher stage throughout the quarter.
We assume that once a person transitions to a higher stage she cannot return to a lower stage. Furthermore, a person in a particular stage has experienced all prior stages in the past, albeit at times unknown to us, unless explicitly documented in prior claims. (2) death. Other diabetes-related health shocks, e.g., heart attacks and strokes,
were not explicitly modeled because they do not a¤ect higher LEC transitions.
Explanatory Variables
Explanatory variables fall into four categories: (1) early diagnosis (our main explanatory variable); (2) duration dependence; (3) demographic variables; and (4) exclusion restrictions.
Early Diagnosis: The e¤ects of early diagnosis are measured using the time with undiagnosed D 1 , D 2 , D 3 , and D 4 and their squares. We de…ned these variables in Section 3. These variables are di¤erent from the duration of the time already spent in the four disease stages after the stage is ascertained by screening. If early diagnosis is bene…cial, then one would expect undiagnosed duration to increase the probability of progression to the next stages and possibly increase mortality and amputation probabilities. Given partial observability of diabetes stages, the e¤ect of these times with undiagnosed disease depend on the integration implicit in eq. (7). 8 We assume that a visit that diagnoses the disease leads to treatment. Thus, earlier diagnosis leads to earlier treatment.
We do not have comprehensive data on treatment.
Duration Dependence: Duration dependence is measured by a quadratic function of the time in quarters from the period the individual enters a particular stage in eqs. (2) and (3). In addition, we allow for a discrete shift in the hazard and probability arguments at entry to any stage. All duration dependence terms can vary independently for each disease stage.
Demographic and Health Characteristics: We include binary variables in all equations for gender, educational attainment, marital status, arthritis, and race. 9 We expect more highly educated and married persons to have better health outcomes. To control for age and cohort e¤ects, we also include a year trend and its square, and the year in which the individual turned age 65. Age and generational changes in diet, for example, might a¤ect diabetes outcomes. in the minimum distance to be negatively related to the probabilities of visits but not to a¤ect disease progression or health shocks after controlling for visits.
Results
Of the 9,417 persons in our sample (col. 1, Panel A, The number of quarters with a visit rises by stage. Healthy individuals visit a physician in 47.8% of the quarters, but once diagnosed with low severity LEC (D 2 ), this probability increases to over 80%. Table 3 are positive, while the parameter estimates on the quadratic terms are negative (row 2). These imply positive but decreasing marginal e¤ects of time without a diagnosis on the hazards of these adverse outcomes occurring. 11 At this disease stage, the principal therapies are drugs, improved diet and more and more regular exercise. These results imply that persons who screen less often for diabetes, and consequently have longer stretches when they have diabetes but are unaware of it, pay a long-term health penalty. Table 4 displays the heterogeneity points of support for the di¤erent transitions and the implied probabilities for each of the eight points of support.
All of the coe¢ cients associated with these mass points and weights are statistically signi…cant. The probabilities associated with the mass points range from 0.012 to 0.326, which indicates that there is no point with extremely small or large weight. Additionally, there are no extreme mass points in any of the speci…cations. The implied correlations between the heterogeneities points of the di¤erent equations (Table 5 ) are mostly positive and small when negative.
This seems plausible in that, for example, the unmeasured heterogeneity associ-ated with faster transitions to D 1 is positively correlated with the unmeasured heterogeneities associated with all disease progressions, amputation, death, and visits.
Marginal E¤ects and Policy Simulations
We conduct two sets of simulations using the parameter estimates in Tables 3   and 4 to describe the bene…ts and costs of di¤erent screening trajectories for diagnosing the onset of diabetes. In the …rst we set we use a very mechanical rule.
We compare longer-term outcomes from the immediate detection of the onset of diabetes to those same outcomes when diabetes progresses and is undetected for exactly four quarters. In the second set we consider somewhat more policy relevant experiments where we restrict the frequency of screening for diabetes to at most only once (or twice) per year; current policy does not restrict the number of times one can be screened for diabetes. We then compare longer-term outcomes from the restricted and unrestricted environments. We simulate 10,000 individuals from age 65 to age 80 for each of these experiments. Demographic characteristics and a diagnosis of arthritis are based on the sample population distribution, and the unmeasured heterogeneity points of support are simulated based on results in Table 4 .
In the …rst set of simulations we impose that the person was healthy at the start of age 65 (t = 4) but becomes diabetic in the next quarter (t = 5).
The experiment is to screen everyone at t = 5 for diabetes and compare those outcomes to ones obtained when there was no screening for diabetes until date t = 9. The former had a zero length period of unobserved diabetes while the latter group experiences exactly one year of undiagnosed diabetes. After the initial screening visit (t = 5 or t = 9) which detects diabetes stage D 1 (or higher for t = 9) with probability one, all subsequent screening visits follow the data generating process described by the full set of parameter estimates. Table 6 In general, these marginal e¤ects are not large, but they are not trivial either.
For the second set of simulations we examine what would happen to life cycle trajectories from age 65 to age 80 if those without a prior diabetes diagnosis were limited to at most only one diabetes screening visit per year. After being observed with diabetes, all subsequent visits (and disease and outcome progressions) follow the processes de…ned by the model estimates. We assume that the …rst visit per year, if there is one, is the screening visit for that year.
We compare these restricted simulated outcomes to the status quo that allows one to make as many screening visits as they would like each year. We also examine a less extreme policy of allowing each person to have up to two diabetes screening visits per year before being observed with diabetes.
In the top row of Table 7 we report cumulative results for the simulations of the status quo over all quarters from age 65 to age 80. In the …rst column we see that with no restrictions on diabetes screening that there would be 38.9 visits on average over this 15-year period. If we were to restrict individuals to have no more than one screening visit before they had been diagnosed with diabetes, the total number of screening visits would fall by 15.6, or about 40% (including the unrestricted ones taking place after the …rst diabetes diagnosis). If instead we limited the number of screening visits for detecting D 1 to at most two per year, there would be 9.54 fewer doctor visits over the 15-year horizon compared to the status quo. These …gures represent the gross cost savings in terms of the number of screening visits prevented by the policies.
The bottom panel of Table 7 In conclusion, this study provides a promising approach for evaluating how the duration of unobserved events a¤ects outcomes of interest using administrative data. Note: All equations include a year trend and its square, and the year in which the individual turned age 65. These 7 equations were estimated jointly with 5 others that describe the diabetes progressions' "initial conditions." Those estimates can be obtained by contacting the corresponding author.
-346,036.05 
Reduction in visits and adverse health outcomes: 15 years follow-up
Only 2 visits/year: The predicted average of the same individuals allowing them to have at most two visit until diagnose with diabetes.
Number of quarters
Appendix A
Likelihood Function
We categorize observations into …ve categories that are de…ned by whether or not we observe an individual progressing to each disease stage. Here we present the likelihood function for each category conditional on the unobserved heterogeneity. We assume away the possibility of reaching diabetes stage 3 (D 3 ) before the time of the …rst post-age 65 screening. where Sur (D 1 = T ) is the probability of an individual surviving to T without
is the probability of having the …rst visit after turning age 65 at t = t F V and Pr V T t F V +1 is the probability of the sequence of visits from t = t F V + 1 to t = T . Pr d T c;t F V for c = 1; 2 is the probability of the sequence of outcomes d ct from t = t F V to t = T .
Category 2: Progress to D 1 at t D1 and did not progressed to D 2 by T : where Sur (D 2 = T j:) is the probability of an individual surviving to T without D 2 after contracting D 1 at t D1 . Pr (D 1 = t D1 j:) is the probability of an individual contracting D 1 at period t D1 which depends on whether t D1 is before or after t F V . There are 3 possible scenarios for Pr (D 1 = t D1 j:): a) if t D1 3 (D 1 before age 65) 
